1. No category

Anaplastic Large Cell
Lymphoma (ALCL)
Therapeutics Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2016-2026
Future Market Insights
www.futuremarketinsights.com
[email protected]
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
Retail.
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for
our client.
Research Capabilities
Sector Coverage








Customized Research
Syndicated Research
Investment Research
Social Media Research
Automotive and Transportation
Electronics, Semiconductor, and ICT
Retail and Consumer Products
Industrial Automation and Equipment
Customized
Research
Subscription Information
Syndicated
Research
For detailed subscription information please contact
Investment
Research
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media
Research
Hari. T (Sr. Manager - Global Business Development)
Email: [email protected]




Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and Gas
Report
Description
Report Description
Lymphoma is the most common type of blood cancer that affects that develops in the
lymphatic system. Lymphoma are of two major types: Hodgkin lymphoma and non-Hodgkin
lymphoma (NHL). Lymphoma is caused when lymphocytes, type of white blood cells of the
immune system grow and multiply uncontrollably. Cancerous lymphocytes may travel to
different parts of the body, including the spleen, blood, lymph nodes, bone marrow, and
form a mass called a tumor. The two type of lymphocytes that can develop into lymphoma –
B-lymphocytes (B-cells) and T-lymphocytes (T-cells). Anaplastic large cell lymphoma (ALCL) is
a rare type of non-Hodgkin lymphoma and a common subtype of T-cell lymphoma. ALCL
consists of only 2% of NHLs and approx. 20% of T-cell lymphomas. ALCL symptoms includes
fever, painless swelling of lymph nodes, weight loss, tiredness, backache and excessive night
sweats. It is comprised of two sub-types, based on the expression of a protein called
anaplastic lymphoma kinase (ALK): ALK positive and ALK negative ALCL
According to National Cancer Institute, in the 2016, an estimated 1,685,210 new cases of
cancer will be diagnosed in the United States and 595,690 people will die from the disease.
NHL is the sixth most commonly diagnosed cancer in both men and women in the US. In
2015, it is estimated that there will be 71,850 new cases of NHL (39,850 men and 32,000
women) and 19,790 deaths from NHL. According to GLOBOCAN 2012 estimates the incidence
and mortality rate of NHL is 2.7% and 2.4% respectively.
Following drugs are being tested for ALCL:
•Alisertib (MLN8237)
•Bortezomib (Velcade)
Report
Description
Report Description
•Combination of brentuximab vedotin and chemotherapy
•Crizotinib (Xalkori)
The global ALCL therapeutics market is segmented on the basis of route of administration,
therapeutic areas and region
Segmentation based on Disease Type
•Primary ALCL
•Relapsed ALCL
Request Free Report @ http://www.futuremarketinsights.com/reports/sample/rep-gb1655
Segmentation based on Treatment Type
•Chemotherapy
• (CHOP) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
• Brentuximab vedotin
• Pralatrexate
•Surgery
•Radiation therapy
Report
Description
Report Description
With the increasing geriatric population and rate of diagnosis will boost the overall market for
ALCL therapeutics. Moreover, significant increase in the healthcare spending will boost the
ALCL therapeutics market during the forecast period.
Geographically the ALCL therapeutics market is segmented into five key regions: North
America, Latin America, Europe, Asia Pacific and MEA region. The areas with the highest
incidence of NHL are North America, Europe, and Australasia, as well as several countries in
Africa and South America. Also, more than 60% of the world’s new cancer cases occur in Africa,
Asia, and Central and South America; 70% of the world’s cancer deaths occur in these regions.
The ALCL can appear on body parts such as skin, organs and other part of the body, they grow
slowly and are present on body for longer duration before diagnosis. ALCL that appears on skin
is known as primary cutaneous ALCL. Most common types of side effects observed are skin
redness and skin irritation is caused. It is being observed that 10 percent primary cutaneous
ALCL extends beyond the skin to organ or lymph. Systemic ALCL is parted depending on
abnormal form of a protein on their surface called ALK or do not have abnormal form of a
protein. These are fast growing and the disease condition in ALK-positive (with abnormal
protein) is different from ALK-negative (without abnormal protein). ALK-positive ALCL patients
are treated with chemotherapy treatments, patients initially respond to the treatment but
relapse within five years, these are found in children’s as well as adults. ALK-negative ALCL
patients are treated with stem cell transplantation after remission, these are mostly found in
patients above 55 years.
Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1655
Report
Description
Report Description
Some major companies in the ALCL therapeutics market are Pfizer, Takeda Pharmaceutical
Company Limited, Teva Pharmaceutical Industries Ltd., Seattle Genetics, Inc., Sareum
Holdings PLC, Merck Sharp & Dohme Corp., Celgene Corporation and Valeant
Pharmaceuticals North America LLC.
Thank You!
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
[email protected]
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705